FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4240810606> ?p ?o ?g. }

• W4240810606 endingPage "679" @default.
• W4240810606 startingPage "679" @default.
• W4240810606 abstract "Abstract Abstract 679 Background: Peripheral T-cell lymphoma (PTCL) represents approximately 10–12% of all non-Hodgkin lymphoma (NHL) in the Western world, with a higher incidence in Asian populations. The World Health Organization classification recognizes a number of distinctive subtypes of PTCL including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), extranodal NK/T-cell lymphoma of nasal type (ENKTCL), and many other rare entities that present mainly as extranodal PTCL. However, with current immunophenotypic and molecular markers, about 30–50% of PTCL cases are not classifiable and are categorized as PTCL-not otherwise specified (PTCL-NOS). With the exception of ALK(+)ALCL, the PTCLs generally have a poor outcome and, thus a better understanding of the biology of these diseases is greatly needed to improve the long-term survival of these patients. Methods: In the current study, we performed gene expression profiling analysis on a large and well- characterized series of PTCL and ENKTCL cases (n=372) from the Lymphoma Leukemia Molecular Profiling Project (LLMPP), the International Peripheral T-cell Lymphoma Project (IPTCL) and other major institutions to define robust molecular classifiers, oncogenic pathways and prognosticators for the more common PTCL entities, as well as unique molecular and prognostic subgroups within PTCL-NOS. Molecular signatures for diagnosis and prognosis were generated in training data sets and validated in separate cohorts. Results: Robust molecular classifiers for AITL, two types of systemic ALCL (ALK(+) and ALK(-)), ATLL and ENKTCL were identified (Figure 1). These classifiers reflect the pathobiology of the tumor cells, as well as their microenvironment, and represent a refinement of what we reported previously (Iqbal et.al Blood, 2010; Iqbal et.al Leukemia. 2011). Importantly, ALK(-)ALCL can be differentiated from ALK(+)ALCL and PTCL-NOS with a unique gene expression signature. Approximately 14% of PTCL-NOS were re-classified as ALK(-)ALCL and showed expression of CD30 protein, TIA-1 or granzyme B by immunohistochemistry. ENKTCL can be separated molecularly into NK-cell lymphoma and gd-PTCL, the latter of which was also identified in 9% of PTCL-NOS. The remaining PTCL-NOS cases could be separated into two major subgroups related to T-cell differentiation and characterized by either high expression of GATA3 (30%) or TBX21(T-BET) (45%) and many of the corresponding target genes (Figure 2). Cases with high expression of GATA3 had poor overall survival and showed enriched Wnt and mTOR pathways, but no prominent microenvironment signature. The high TBX21 subgroup had a remarkably good outcome for patients with a high plasma cell-like gene expression signature, but poor overall survival when expressing a high cytotoxic signature (Figure 3). The molecular prognosticator for AITL largely reflected the role of the tumor microenvironment, with the presence of a high B-cell signature correlating with favorable outcome, whereas high dendritic cell/monocyte signatures were associated with inferior survival. Conclusion: We have organized the most comprehensive molecular profiling study of PTCL, and have not only refined the molecular diagnostic and prognostic signatures for the common subtypes of PTCL, but also segregated PTCL-NOS in meaningful biological and prognostic subtypes. Molecular diagnostic and prognostic signatures of PTCL frequently include components of the tumor-host interactions, highlighting the importance of the microenvironment in PTCL biology. This study provides an important framework for additional analysis to identify novel therapeutic targets to improve the outcome of patients with PTCL. Disclosures: No relevant conflicts of interest to declare." @default.
• W4240810606 created "2022-05-12" @default.
• W4240810606 creator A5012900514 @default.
• W4240810606 creator A5014743270 @default.
• W4240810606 creator A5015247283 @default.
• W4240810606 creator A5022164102 @default.
• W4240810606 creator A5025942951 @default.
• W4240810606 creator A5027498478 @default.
• W4240810606 creator A5027607201 @default.
• W4240810606 creator A5029161067 @default.
• W4240810606 creator A5031758990 @default.
• W4240810606 creator A5035399907 @default.
• W4240810606 creator A5037413392 @default.
• W4240810606 creator A5039053890 @default.
• W4240810606 creator A5043985252 @default.
• W4240810606 creator A5046438171 @default.
• W4240810606 creator A5047622301 @default.
• W4240810606 creator A5051379368 @default.
• W4240810606 creator A5053906265 @default.
• W4240810606 creator A5055838753 @default.
• W4240810606 creator A5059707915 @default.
• W4240810606 creator A5061471602 @default.
• W4240810606 creator A5061884206 @default.
• W4240810606 creator A5066731616 @default.
• W4240810606 creator A5074135845 @default.
• W4240810606 creator A5076637635 @default.
• W4240810606 creator A5080373697 @default.
• W4240810606 creator A5081888684 @default.
• W4240810606 creator A5086207316 @default.
• W4240810606 creator A5089779163 @default.
• W4240810606 date "2012-11-16" @default.
• W4240810606 modified "2023-09-30" @default.
• W4240810606 title "Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma" @default.
• W4240810606 doi "https://doi.org/10.1182/blood.v120.21.679.679" @default.
• W4240810606 hasPublicationYear "2012" @default.
• W4240810606 type Work @default.
• W4240810606 citedByCount "2" @default.
• W4240810606 countsByYear W42408106062014 @default.
• W4240810606 countsByYear W42408106062015 @default.
• W4240810606 crossrefType "journal-article" @default.
• W4240810606 hasAuthorship W4240810606A5012900514 @default.
• W4240810606 hasAuthorship W4240810606A5014743270 @default.
• W4240810606 hasAuthorship W4240810606A5015247283 @default.
• W4240810606 hasAuthorship W4240810606A5022164102 @default.
• W4240810606 hasAuthorship W4240810606A5025942951 @default.
• W4240810606 hasAuthorship W4240810606A5027498478 @default.
• W4240810606 hasAuthorship W4240810606A5027607201 @default.
• W4240810606 hasAuthorship W4240810606A5029161067 @default.
• W4240810606 hasAuthorship W4240810606A5031758990 @default.
• W4240810606 hasAuthorship W4240810606A5035399907 @default.
• W4240810606 hasAuthorship W4240810606A5037413392 @default.
• W4240810606 hasAuthorship W4240810606A5039053890 @default.
• W4240810606 hasAuthorship W4240810606A5043985252 @default.
• W4240810606 hasAuthorship W4240810606A5046438171 @default.
• W4240810606 hasAuthorship W4240810606A5047622301 @default.
• W4240810606 hasAuthorship W4240810606A5051379368 @default.
• W4240810606 hasAuthorship W4240810606A5053906265 @default.
• W4240810606 hasAuthorship W4240810606A5055838753 @default.
• W4240810606 hasAuthorship W4240810606A5059707915 @default.
• W4240810606 hasAuthorship W4240810606A5061471602 @default.
• W4240810606 hasAuthorship W4240810606A5061884206 @default.
• W4240810606 hasAuthorship W4240810606A5066731616 @default.
• W4240810606 hasAuthorship W4240810606A5074135845 @default.
• W4240810606 hasAuthorship W4240810606A5076637635 @default.
• W4240810606 hasAuthorship W4240810606A5080373697 @default.
• W4240810606 hasAuthorship W4240810606A5081888684 @default.
• W4240810606 hasAuthorship W4240810606A5086207316 @default.
• W4240810606 hasAuthorship W4240810606A5089779163 @default.
• W4240810606 hasConcept C117643217 @default.
• W4240810606 hasConcept C126322002 @default.
• W4240810606 hasConcept C142724271 @default.
• W4240810606 hasConcept C143998085 @default.
• W4240810606 hasConcept C203014093 @default.
• W4240810606 hasConcept C2776090121 @default.
• W4240810606 hasConcept C2776232967 @default.
• W4240810606 hasConcept C2776256026 @default.
• W4240810606 hasConcept C2777547418 @default.
• W4240810606 hasConcept C2777589544 @default.
• W4240810606 hasConcept C2777872185 @default.
• W4240810606 hasConcept C2777891184 @default.
• W4240810606 hasConcept C2778461978 @default.
• W4240810606 hasConcept C2779338263 @default.
• W4240810606 hasConcept C502942594 @default.
• W4240810606 hasConcept C71924100 @default.
• W4240810606 hasConcept C8891405 @default.
• W4240810606 hasConceptScore W4240810606C117643217 @default.
• W4240810606 hasConceptScore W4240810606C126322002 @default.
• W4240810606 hasConceptScore W4240810606C142724271 @default.
• W4240810606 hasConceptScore W4240810606C143998085 @default.
• W4240810606 hasConceptScore W4240810606C203014093 @default.
• W4240810606 hasConceptScore W4240810606C2776090121 @default.
• W4240810606 hasConceptScore W4240810606C2776232967 @default.
• W4240810606 hasConceptScore W4240810606C2776256026 @default.
• W4240810606 hasConceptScore W4240810606C2777547418 @default.
• W4240810606 hasConceptScore W4240810606C2777589544 @default.
• W4240810606 hasConceptScore W4240810606C2777872185 @default.
• W4240810606 hasConceptScore W4240810606C2777891184 @default.
• W4240810606 hasConceptScore W4240810606C2778461978 @default.

• next